Vijay Kumar
Stock Analyst at Evercore ISI Group
(2.35)
# 2,461
Out of 5,182 analysts
289
Total ratings
45.03%
Success rate
-2.06%
Average return
Main Sectors:
Stocks Rated by Vijay Kumar
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EW Edwards Lifesciences | Maintains: Outperform | $92 → $93 | $83.46 | +11.43% | 17 | Apr 24, 2026 | |
| BSX Boston Scientific | Maintains: Outperform | $80 → $78 | $59.95 | +30.11% | 10 | Apr 23, 2026 | |
| ABT Abbott Laboratories | Maintains: Outperform | $134 → $120 | $92.80 | +29.31% | 20 | Apr 17, 2026 | |
| MDT Medtronic | Maintains: Outperform | $108 → $106 | $82.92 | +27.83% | 7 | Apr 9, 2026 | |
| MTD Mettler-Toledo International | Maintains: Outperform | $1,515 → $1,425 | $1,274.70 | +11.79% | 13 | Apr 6, 2026 | |
| USB U.S. Bancorp | Maintains: In-Line | $65 → $58 | $55.97 | +3.63% | 9 | Apr 6, 2026 | |
| TWST Twist Bioscience | Maintains: Outperform | $52 → $56 | $61.00 | -8.20% | 8 | Apr 6, 2026 | |
| TMO Thermo Fisher Scientific | Maintains: Outperform | $650 → $575 | $468.04 | +22.85% | 14 | Apr 6, 2026 | |
| SYK Stryker | Maintains: Outperform | $400 → $365 | $329.01 | +10.94% | 14 | Apr 6, 2026 | |
| ISRG Intuitive Surgical | Maintains: In-Line | $550 → $480 | $470.99 | +1.91% | 16 | Apr 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $210 → $170 | $125.96 | +34.96% | 4 | Apr 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $98 → $85 | $70.48 | +20.60% | 7 | Apr 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $36 → $35 | $24.54 | +42.62% | 5 | Apr 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $254 → $225 | $180.62 | +24.57% | 5 | Apr 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $34 → $30 | $19.93 | +50.53% | 4 | Apr 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: In-Line | $18 → $17 | $15.88 | +7.05% | 13 | Apr 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $23 → $22 | $18.49 | +18.98% | 9 | Apr 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $45 → $35 | $25.15 | +39.17% | 11 | Apr 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: In-Line | $10 → $8.5 | $7.97 | +6.65% | 14 | Apr 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $160 → $140 | $115.62 | +21.09% | 9 | Apr 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $222 → $232 | $250.16 | -7.26% | 10 | Mar 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $340 → $360 | $327.98 | +9.76% | 3 | Feb 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $112 → $118 | $86.80 | +35.94% | 4 | Feb 3, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $94 → $120 | $92.59 | +29.60% | 15 | Jan 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $132 → $142 | $128.52 | +10.49% | 9 | Oct 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: In-Line | $3 | $3.01 | -0.33% | 6 | May 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $18 → $30 | $12.48 | +140.38% | 11 | Dec 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: In-Line | $335 → $355 | $299.79 | +18.42% | 8 | Oct 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $120 → $160 | $98.28 | +62.80% | 7 | Oct 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $286 → $290 | $150.22 | +93.05% | 6 | Oct 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $7 | $1.30 | +438.46% | 1 | May 31, 2022 |
Edwards Lifesciences
Apr 24, 2026
Maintains: Outperform
Price Target: $92 → $93
Current: $83.46
Upside: +11.43%
Boston Scientific
Apr 23, 2026
Maintains: Outperform
Price Target: $80 → $78
Current: $59.95
Upside: +30.11%
Abbott Laboratories
Apr 17, 2026
Maintains: Outperform
Price Target: $134 → $120
Current: $92.80
Upside: +29.31%
Medtronic
Apr 9, 2026
Maintains: Outperform
Price Target: $108 → $106
Current: $82.92
Upside: +27.83%
Mettler-Toledo International
Apr 6, 2026
Maintains: Outperform
Price Target: $1,515 → $1,425
Current: $1,274.70
Upside: +11.79%
U.S. Bancorp
Apr 6, 2026
Maintains: In-Line
Price Target: $65 → $58
Current: $55.97
Upside: +3.63%
Twist Bioscience
Apr 6, 2026
Maintains: Outperform
Price Target: $52 → $56
Current: $61.00
Upside: -8.20%
Thermo Fisher Scientific
Apr 6, 2026
Maintains: Outperform
Price Target: $650 → $575
Current: $468.04
Upside: +22.85%
Stryker
Apr 6, 2026
Maintains: Outperform
Price Target: $400 → $365
Current: $329.01
Upside: +10.94%
Intuitive Surgical
Apr 6, 2026
Maintains: In-Line
Price Target: $550 → $480
Current: $470.99
Upside: +1.91%
Apr 6, 2026
Maintains: Outperform
Price Target: $210 → $170
Current: $125.96
Upside: +34.96%
Apr 6, 2026
Maintains: Outperform
Price Target: $98 → $85
Current: $70.48
Upside: +20.60%
Apr 6, 2026
Maintains: Outperform
Price Target: $36 → $35
Current: $24.54
Upside: +42.62%
Apr 6, 2026
Maintains: Outperform
Price Target: $254 → $225
Current: $180.62
Upside: +24.57%
Apr 6, 2026
Maintains: Outperform
Price Target: $34 → $30
Current: $19.93
Upside: +50.53%
Apr 6, 2026
Maintains: In-Line
Price Target: $18 → $17
Current: $15.88
Upside: +7.05%
Apr 6, 2026
Maintains: Outperform
Price Target: $23 → $22
Current: $18.49
Upside: +18.98%
Apr 6, 2026
Maintains: Outperform
Price Target: $45 → $35
Current: $25.15
Upside: +39.17%
Apr 6, 2026
Maintains: In-Line
Price Target: $10 → $8.5
Current: $7.97
Upside: +6.65%
Apr 6, 2026
Maintains: Outperform
Price Target: $160 → $140
Current: $115.62
Upside: +21.09%
Mar 27, 2026
Maintains: Outperform
Price Target: $222 → $232
Current: $250.16
Upside: -7.26%
Feb 26, 2026
Maintains: Outperform
Price Target: $340 → $360
Current: $327.98
Upside: +9.76%
Feb 3, 2026
Maintains: Outperform
Price Target: $112 → $118
Current: $86.80
Upside: +35.94%
Jan 5, 2026
Upgrades: Outperform
Price Target: $94 → $120
Current: $92.59
Upside: +29.60%
Oct 31, 2025
Maintains: Outperform
Price Target: $132 → $142
Current: $128.52
Upside: +10.49%
May 19, 2025
Maintains: In-Line
Price Target: $3
Current: $3.01
Upside: -0.33%
Dec 2, 2024
Upgrades: Outperform
Price Target: $18 → $30
Current: $12.48
Upside: +140.38%
Oct 1, 2024
Maintains: In-Line
Price Target: $335 → $355
Current: $299.79
Upside: +18.42%
Oct 1, 2024
Maintains: Outperform
Price Target: $120 → $160
Current: $98.28
Upside: +62.80%
Oct 1, 2024
Maintains: Outperform
Price Target: $286 → $290
Current: $150.22
Upside: +93.05%
May 31, 2022
Initiates: Outperform
Price Target: $7
Current: $1.30
Upside: +438.46%